Cell-based therapy for bronchopulmonary dysplasia in preterm infants

2019 ◽  
Vol 97 (3) ◽  
pp. 232-234 ◽  
Author(s):  
Mireille Guillot ◽  
Martin Offringa ◽  
Thierry Lacaze-Masmonteil ◽  
Bernard Thébaud
Keyword(s):  
Stem Cells ◽  
Cell Therapy ◽  
Preterm Infants ◽  
Bronchopulmonary Dysplasia ◽  
Phase Ii ◽  
Health Care Providers ◽  
Phase Ii Trial ◽  
Specific Treatment ◽  
Care Providers ◽  
Cell Based Therapy

Bronchopulmonary dysplasia (BPD) is the most common complication of extreme prematurity. Currently, there is no specific treatment available. Preclinical studies support cell therapy as a promising therapy for BPD in preterm infants. A successful translation to a safe and effective clinical intervention depends on multiple factors including the perspective of neonatal health care providers. A 2-hour workshop with 40 Canadian neonatologists was held to enhance the design of a phase II trial of stem cells for babies at risk for BPD, with a focus on the population to target and the outcomes to measure in such a trial. The consensus was that infants recruited in an early trial of stem cells should be the ones with the highest risk of developing severe BPD. This risk should be established based on known antenatal, perinatal, and postnatal risk factors. The primary outcome in a phase II trial will be focussed on a non-clinical outcome (e.g., a dose-finding study or a safety study). With other aspects of a translational study discussed, this workshop contributed to accelerate the design of a first Canadian clinical cell-therapy study for BPD in preterm infants.

scholarly journals Stem cells for bronchopulmonary dysplasia in preterm infants: A randomized controlled phase II trial

2021 ◽  
Author(s):  
So Yoon Ahn ◽  
Yun Sil Chang ◽  
Myung Hee Lee ◽  
Se In Sung ◽  
Byong Sop Lee ◽  
...  
Keyword(s):  
Stem Cells ◽  
Preterm Infants ◽  
Bronchopulmonary Dysplasia ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Randomized Controlled

scholarly journals Strategies to Improve the Quality and Freshness of Human Bone Marrow-Derived Mesenchymal Stem Cells for Neurological Diseases

2021 ◽  
Vol 2021 ◽  
pp. 1-15
Author(s):  
Da Yeon Lee ◽  
Sung Eun Lee ◽  
Do Hyeon Kwon ◽  
Saraswathy Nithiyanandam ◽  
Mi Ha Lee ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Cell Therapy ◽  
Neurological Diseases ◽  
Human Bone ◽  
Human Bone Marrow ◽  
Culture Dish ◽  
Cell Based Therapy ◽  
The Brain

Human bone marrow-derived mesenchymal stem cells (hBM-MSCs) have been studied for their application to manage various neurological diseases, owing to their anti-inflammatory, immunomodulatory, paracrine, and antiapoptotic ability, as well as their homing capacity to specific regions of brain injury. Among mesenchymal stem cells, such as BM-MSCs, adipose-derived MSCs, and umbilical cord MSCs, BM-MSCs have many merits as cell therapeutic agents based on their widespread availability and relatively easy attainability and in vitro handling. For stem cell-based therapy with BM-MSCs, it is essential to perform ex vivo expansion as low numbers of MSCs are obtained in bone marrow aspirates. Depending on timing, before hBM-MSC transplantation into patients, after detaching them from the culture dish, cell viability, deformability, cell size, and membrane fluidity are decreased, whereas reactive oxygen species generation, lipid peroxidation, and cytosolic vacuoles are increased. Thus, the quality and freshness of hBM-MSCs decrease over time after detachment from the culture dish. Especially, for neurological disease cell therapy, the deformability of BM-MSCs is particularly important in the brain for the development of microvessels. As studies on the traditional characteristics of hBM-MSCs before transplantation into the brain are very limited, omics and machine learning approaches are needed to evaluate cell conditions with indepth and comprehensive analyses. Here, we provide an overview of hBM-MSCs, the application of these cells to various neurological diseases, and improvements in their quality and freshness based on integrated omics after detachment from the culture dish for successful cell therapy.

scholarly journals Effects of Perinatal Testosterone on Infant Health, Mother–Infant Interactions, and Infant Development

2013 ◽  
Vol 16 (2) ◽  
pp. 228-236 ◽  
Author(s):  
June Cho ◽  
Diane Holditch-Davis
Keyword(s):  
Gender Differences ◽  
Conceptual Framework ◽  
Preterm Infants ◽  
Health Care Providers ◽  
Infant Development ◽  
Infant Health ◽  
Very Low Birth Weight ◽  
Nursing Interventions ◽  
Care Providers ◽  
Health And Development

Objective: Many researchers and health care providers have noticed male vulnerability in infant health, mother–infant interactions, and some infant cognitive development, especially among very low birth weight (VLBW) preterm infants. However, factors beyond gender that could explain these observed differences have not been clear. The purpose of this article is to review the literature on the subject and to introduce a conceptual framework relating these factors. Discussion: According to gender-difference theories, prenatal exposure to high levels of testosterone may influence infant health and mother–infant interactions by negatively affecting infant cognitive/motor/language development. We constructed a conceptual framework based on the associations among biological (perinatal testosterone), stress-related (perinatal and maternal cortisol), and developmental (infant cognitive/motor/language skills) factors. If research establishes these biological, environmental, and developmental associations in mother–VLBW preterm pairs, the results will highlight the importance of addressing gender differences in nursing research and encourage the development of nursing interventions designed to reduce stress among mothers of VLBW preterm infants, particularly male infants. Conclusion: From a psychobiosocial perspective, combining biophysiological factors such as perinatal testosterone and cortisol with socioenvironmental factors such as the quality of mother–infant interactions and infant temperament may provide a broader view of gender differences in infant health and development.

Mesenchymal Stromal Cell Therapy for Respiratory Complications of Extreme Prematurity

2018 ◽  
Vol 35 (06) ◽  
pp. 566-569 ◽  
Author(s):  
Bernard Thébaud
Keyword(s):  
Cell Therapy ◽  
Preterm Infants ◽  
Bronchopulmonary Dysplasia ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Organ Damage ◽  
Cell Therapies ◽  
Neonatal Lung ◽  
Neonatal Lung Injury ◽  
Early Phase Clinical Trials

AbstractBronchopulmonary dysplasia remains the main complication of extreme preterm birth. Research over the past 10 years suggests the potential for stem cell-based therapies to prevent and/or restore organ damage in extreme preterm infants. Mesenchymal stromal cells, in particular, have advanced as the forerunner among various cell therapies based on very promising preclinical studies in animal models of neonatal lung injury. Early phase clinical trials are now underway to determine the safety and feasibility of this cell therapy in preterm infants at risk of developing bronchopulmonary dysplasia. This review will summarize the current rationale for testing mesenchymal stromal cells in this patient population and highlight the gaps in our knowledge to safely harness the full repair potential of cell-based therapies.

scholarly journals Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial

2020 ◽  
Vol 35 (8) ◽  
pp. 1323-1335 ◽  
Author(s):  
Anne‐Catherine Bachoud‐Lévi ◽  
Catherine Schramm ◽  
Philippe Remy ◽  
Ghislaine Aubin ◽  
Serge Blond ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Fetal Cell ◽  
Multicenter Phase

scholarly journals Therapeutic options in post-transplant lymphoproliferative disorders

2011 ◽  
Vol 2 (6) ◽  
pp. 393-407 ◽  
Author(s):  
Heiner Zimmermann ◽  
Ralf Ulrich Trappe
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Solid Organ Transplantation ◽  
Lymphoproliferative Disorders ◽  
Treatment Modalities ◽  
Cytotoxic T Cell ◽  
Solid Organ ◽  
T Cell Therapy

Post-transplantation lymphoproliferative disorders (PTLD) are the second most frequent malignancies after solid organ transplantation and cover a wide spectrum ranging from polyclonal early lesions to monomorphic lymphoma. Available treatment modalities include immunosuppression reduction, immunotherapy with anti-B-cell monoclonal antibodies, chemotherapy, antiviral therapy, cytotoxic T-cell therapy as well as surgery and irradiation. Owing to the small number of cases and the heterogeneity of PTLD, current treatment strategies are mostly based on case reports and small, often retrospective studies. Moreover, many studies on the treatment of PTLD have involved a combination of different treatment options, complicating the evaluation of individual treatment components. However, there has been significant progress over the last few years. Three prospective phase II trials on the efficacy of rituximab monotherapy have shown significant complete remission rates without any relevant toxicity. A prospective, multicenter, international phase II trial evaluating sequential treatment with rituximab and CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) is ongoing and preliminary results have been promising. Cytotoxic T-cell therapy targeting Epstein–Barr virus (EBV)-infected B cells has shown low toxicity and high efficacy in a phase II trial and will be a future therapeutic option at specialized centers. Here, we review the currently available data on the different treatment modalities with a focus on PTLD following solid organ transplantation in adult patients.

scholarly journals Cell-Based Therapy for Stroke

Stroke ◽  
2020 ◽  
Vol 51 (9) ◽  
pp. 2854-2862 ◽  
Author(s):  
You Jeong Park ◽  
Kuniyasu Niizuma ◽  
Maxim Mokin ◽  
Mari Dezawa ◽  
Cesar V. Borlongan
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Ischemic Stroke ◽  
Cell Therapy ◽  
Therapeutic Potential ◽  
Host Tissue ◽  
In Vivo Models ◽  
Cell Based Therapy ◽  
Muse Cells

Stem cell-based regenerative therapies may rescue the central nervous system following ischemic stroke. Mesenchymal stem cells exhibit promising regenerative capacity in in vitro studies but display little to no incorporation in host tissue after transplantation in in vivo models of stroke. Despite these limitations, clinical trials using mesenchymal stem cells have produced some functional benefits ascribed to their ability to modulate the host’s inflammatory response coupled with their robust safety profile. Regeneration of ischemic brain tissue using stem cells, however, remains elusive in humans. Multilineage-differentiating stress-enduring (Muse) cells are a distinct subset of mesenchymal stem cells found sporadically in connective tissue of nearly every organ. Since their discovery in 2010, these endogenous reparative stem cells have been investigated for their therapeutic potential against a variety of diseases, including acute myocardial infarction, stroke, chronic kidney disease, and liver disease. Preclinical studies have exemplified Muse cells’ unique ability mobilize, differentiate, and engraft into damaged host tissue. Intravenously transplanted Muse cells in mouse lacunar stroke models afforded functional recovery and long-term engraftment into the host neural network. This mini-review article highlights these biological properties that make Muse cells an exceptional candidate donor source for cell therapy in ischemic stroke. Elucidating the mechanism behind the therapeutic potential of Muse cells will undoubtedly help optimize stem cell therapy for stroke and advance the field of regenerative medicine.

scholarly journals Application of Nanotechnology in Stem-Cell-Based Therapy of Neurodegenerative Diseases

2020 ◽  
Vol 10 (14) ◽  
pp. 4852 ◽  
Author(s):  
Shima Masoudi Asil ◽  
Jyoti Ahlawat ◽  
Gileydis Guillama Barroso ◽  
Mahesh Narayan
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Large Scale ◽  
Stem Cell Differentiation ◽  
Cell Types ◽  
Clinical Scales ◽  
Adverse Health Outcomes ◽  
Cell Based Therapy

In addition to adverse health outcomes, neurological disorders have serious societal and economic impacts on patients, their family and society as a whole. There is no definite treatment for these disorders, and current available drugs only slow down the progression of the disease. In recent years, application of stem cells has been widely advanced due to their potential of self-renewal and differentiation to different cell types which make them suitable candidates for cell therapy. In particular, this approach offers great opportunities for the treatment of neurodegenerative disorders. However, some major issues related to stem-cell therapy, including their tumorigenicity, viability, safety, metastases, uncontrolled differentiation and possible immune response have limited their application in clinical scales. To address these challenges, a combination of stem-cell therapy with nanotechnology can be a solution. Nanotechnology has the potential of improvement of stem-cell therapy by providing ideal substrates for large scale proliferation of stem cells. Application of nanomaterial in stem-cell culture will be also beneficial to modulation of stem-cell differentiation using nanomedicines. Nanodelivery of functional compounds can enhance the efficiency of neuron therapy by stem cells and development of nanobased techniques for real-time, accurate and long-lasting imaging of stem-cell cycle processes. However, these novel techniques need to be investigated to optimize their efficiency in treatment of neurologic diseases.

Sign in / Sign up

Export Citation Format

Share Document